<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180969</url>
  </required_header>
  <id_info>
    <org_study_id>TSM-1</org_study_id>
    <nct_id>NCT04180969</nct_id>
  </id_info>
  <brief_title>rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers</brief_title>
  <acronym>TSM-1</acronym>
  <official_title>Impact of Repetitive Transcranial Magnetic Stimulation (rTMS) of Limbic Brain Circuitry in Stress Modulation in a Healthy Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted with healthy male and female participants. Aim 1 will determine&#xD;
      during sham repetitive transcranial magnetic stimulation (rTMS) how a drug stressor&#xD;
      combination (yohimbine + hydrocortisone) relative to placebo alters : (1a) impulsivity; (1b)&#xD;
      mood; and (1c) physiology. Aim 2 will determine whether active rTMS over the medial&#xD;
      prefrontal cortex alters the effects of stress-exposure on (2a) decision-making, (2b) mood,&#xD;
      and (2c) biomarkers of stress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use a double-blind, within-subjects randomized crossover design. Each&#xD;
      participant will complete 4 sessions in this two-factor (2x2) combinatorial design: 1Hz&#xD;
      medial prefrontal cortex (mPFC) vs. sham repetitive transcranial magnetic stimulation (rTMS)&#xD;
      X pharmacological stressor (yohimbine 54mg + hydrocortisone 20mg) vs. placebo, with each&#xD;
      session separated by at least 1 week. Participants will be asked not to use alcohol or drugs&#xD;
      for 24-hr before arriving at the lab. We expect to complete screen at least 20 individuals to&#xD;
      complete 12 individuals in this study. Candidates will first undergo psychiatric and medical&#xD;
      screening to rule out contraindications to participation. Once enrolled, each participant&#xD;
      will complete, in randomized order, the 4 conditions above. Periodic measures will be&#xD;
      collected before and after the rTMS/sham and stress/placebo interventions. These measures&#xD;
      will include subjective, behavioral and physiological assessments, as well as saliva and&#xD;
      blood samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind, 1Hz mPFC (vs. sham) rTMS X stressor (vs. placebo), 4-session, within-subjects, randomized crossover design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>sham (inactive) figure of 8 coil for rTMS, and placebo for pharmacological stressor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Color-Word Stroop Task</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>reaction time (msec) measure of cognitive interference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Span Task</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>number of digits recalled, measure of verbal working memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wisconsin Card Sorting Task</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>number of correct items, measure of ability to shift set and assesses cognitive flexibility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monetary Incentive Delay Task</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>number of rewards received, measure of motivation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delay Discounting Task</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>rate of monetary discounting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effort Choice Task</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>number of progressive ratio (PR) choices vs. fixed ratio (FR) choices</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) positive affect</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>10-item questionnaire sub scale that measures positive affect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) negative affect</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>10-item questionnaire sub scale that measures negative affect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>questionnaire subscale that measures state anxiety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>Heart rate (beats/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saliva cortisol level</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>Saliva cortisol level (Âµg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saliva alpha-amylase level</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>Saliva alpha-amylase level (U/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma prolactin level</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>Plasma prolactin level (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma BDNF level</measure>
    <time_frame>change from pre- to post-intervention in each of the 4 sessions (through study completion, about 1 month total)</time_frame>
    <description>Plasma brain derived neurotrophic factor level (pg/mL)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stress</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>placebo stressor, sham rTMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo stressor, active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active stress, sham rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active stress, active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>yohimbine + hydrocortisone</intervention_name>
    <description>yohimbine 54mg + hydrocortisone 20mg oral</description>
    <arm_group_label>active stress, active rTMS</arm_group_label>
    <arm_group_label>active stress, sham rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>medial prefrontal cortex rTMS</intervention_name>
    <description>1 Hz mPFC rTMS</description>
    <arm_group_label>active stress, active rTMS</arm_group_label>
    <arm_group_label>placebo stressor, active rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>placebo stressor</description>
    <arm_group_label>placebo stressor, active rTMS</arm_group_label>
    <arm_group_label>placebo stressor, sham rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham rTMS</intervention_name>
    <description>sham mPFC rTMS</description>
    <arm_group_label>active stress, sham rTMS</arm_group_label>
    <arm_group_label>placebo stressor, sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21-60 yr&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Males and non-pregnant/non-lactating females&#xD;
&#xD;
          -  Cognitively intact (total IQ score &gt;80 on Shipley Institute of Living Scale)&#xD;
&#xD;
          -  Screening cardiovascular indices must be within ranges that allow for safe use of&#xD;
             stressor: resting HR 50-90 bpm, systolic BP 90-140 mmHg, and diastolic BP 50-90 mmHg&#xD;
&#xD;
          -  Use alcohol and/or marijuana &lt;3 times/week; each &quot;time&quot; should consist of &lt;1 marijuana&#xD;
             &quot;joint&quot; equivalent and &lt;3 alcoholic drinks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under influence of any substance during session&#xD;
&#xD;
          -  Past 7-day use of illicit drugs (excluding marijuana) based on Timeline Followback&#xD;
             interview&#xD;
&#xD;
          -  Urine positive for opioids, cocaine metabolites, benzodiazepines, barbiturates,&#xD;
             amphetamines or pregnancy&#xD;
&#xD;
          -  Medical conditions prohibiting use of rTMS (e.g. seizure history; using validated rTMS&#xD;
             screening instrument)&#xD;
&#xD;
          -  Lifetime diagnosis of: psychotic disorder, bipolar disorder, generalized anxiety&#xD;
             disorder, obsessive compulsive disorder, or major depression that is not&#xD;
             substance-induced&#xD;
&#xD;
          -  Past-year substance use disorder&#xD;
&#xD;
          -  Medical conditions making it unsafe for participation (e.g. neurological,&#xD;
             cardiovascular, pulmonary, or systemic diseases)&#xD;
&#xD;
          -  Lactose intolerance (placebo dose)&#xD;
&#xD;
          -  Any prohibited medications: medications that lower seizure threshold, psychiatric&#xD;
             medications, prescription pain medications, or blood pressure medications&#xD;
&#xD;
          -  Chronic head or neck pain&#xD;
&#xD;
          -  Taken part in any research studies in the past month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark K Greenwald, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tabitha Moses</last_name>
    <phone>313-577-8257</phone>
    <email>druglabdetroit@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark K Greenwald, PhD</last_name>
    <phone>313-993-3965</phone>
    <email>mgreen@med.wayne.edu</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Mark Greenwald, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Yohimbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Full sharing plan is being developed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Materials will only become available after the study is completed and the first manuscript from this project is published.</ipd_time_frame>
    <ipd_access_criteria>Qualified investigators may apply in writing to Dr. Greenwald</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

